MODELING DEPRESSION
- Authors: Borozdenko D.A.1, Khovanova S.S1, Kiseleva N.M1, Negrebetsky V.V1
-
Affiliations:
- N.I. Pirigov Russian National Research Medical University
- Issue: Vol 25, No 3 (2019)
- Pages: 176-180
- Section: Articles
- URL: https://journals.rcsi.science/0869-2106/article/view/44149
- DOI: https://doi.org/10.18821/0869-2106-2019-25-3-176-180
- ID: 44149
Cite item
Full Text
Abstract
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Denis A. Borozdenko
N.I. Pirigov Russian National Research Medical University
Email: borozdenko@phystech.edu
assistant of the Department of pharmacology, N.I. Pirogov Russian National Research Medical University, Moscow, 117997, Russian Federation 117997, Moscow, Russian Federation
S. S Khovanova
N.I. Pirigov Russian National Research Medical University117997, Moscow, Russian Federation
N. M Kiseleva
N.I. Pirigov Russian National Research Medical University117997, Moscow, Russian Federation
Vad. V Negrebetsky
N.I. Pirigov Russian National Research Medical University117997, Moscow, Russian Federation
References
- World Health Organization Depression and Other Common Mental Disorders: Global Health Estimates. World Health Organization 2017. Available at: https://apps.who.int/iris/bitstream/handle/10665/254610/WHO-MSD-MER-2017.2-eng.pdf;jsessionid=FB3E403FCB4E2C4C7001C450A1CB23B5?sequence=1.
- Sullivan P. F., Neale M.C., Kendler K.S. Genetic Epidemiology of Major Depression: Review and Meta-Analysis. American Journal of Psychiatry. 2000; 157(10): 1552-62.
- McGuffin P., Cohen S., Knight J. Homing in on Depression Genes. American Journal of Psychiatry. 2007; 164(2): 195-7.
- Menke A., Klengel T., Binder B.E. Epigenetics, Depression and Antidepressant Treatment. Current.Pharmaceutical Design. 2012; 18(36): 5879-89.
- Deverteuil R.L., Lehmann H.E. Therapeutic trial of iproniazid (marsilid) in depressed and apathetic patients. Can Med Assoc J. 1958; 78: 131-3.
- Kraft J.B., Slager S.L., McGrath P.J., Hamilton S.P. Sequence analysis of the serotonin transporter and associations with antidepressant response. Biol Psychiatry. 2005; 58: 374-81.
- Hu X.Z., Lipsky R.H., Zhu G., Akhtar L.A., Taubman J., Greenberg B.D. et al. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am J Hum Genet. 2006; 78: 815-26.
- Kuhn R. The treatment of depressive states with G 22355 (imipramine hydrochloride). Am J Psychiatry. 1958; 115: 459-64.
- Schildkraut J.J., Kety S.S. Biogenic amines and emotion. Science. 1967; 156: 21-37.
- Bao A.M., Meynen G., Swaab D.F. The stress system in depression and neurodegeneration: focus on the human hypothalamus. Brain Res Rev. 2008; 57: 531-53.
- Парфенов В.А. Постинсультная депрессия: распространенность, патогенез, диагностика и лечение. Неврология, нейропсихиатрия, психосоматика. 2012;4(4):84-88.
- Образовательная программа по депрессивным расстройствам. Всемирная психиатрическая ассоциация расстройствам Mario Maj, Norman Sartorius, Allan Tasman, Oye Gureje, пер. на рус. яз. вып. в Московском НИИ психиатрии под ред. проф. Краснова В.Н., 2010 Available at: http://bekhterev.ru/content/43/OT1.pdf.
- Thase ME. Depression and sleep: pathophysiology and treatment. Dialogues Clin Neurosci. 2006; 8(2): 217-226.
- Kumar A., Newberg A., Alavi A., Berlin J., Smith R., Reivich M. Regional cerebral glucose metabolism in late-life depression and Alzheimer disease: a preliminary positron emission tomography study. Proc Natl Acad Sci U S A. 1993; 90(15): 7019-23.
- Бауэр М., Пфенниг А., Северус Э., Вайбрау П.С., Ангст Ж., Мюллер Х.-Ю. Клинические рекомендации Всемирной федерации обществ биологической психиатрии по биологической терапии униполярных депрессивных расстройств. Современная терапия психических расстройств. 2016;1: 31-48
- The National Institute for Health and Care Excellence (NICE) Depression in adults: recognition and management. Clinical guideline [CG90]. NICE. 2018. Available at: https://www.nice.org.uk/guidance/cg90
- Seltzer V., Tonge S.R. Methylamphetamine withdrawal as a model for the depressive state: antagonism of post-amphetamine depression by imipramine. J Pharm Pharmacol. 1975; 27 Suppl 2.
- Григорьян Г.А., Гуляева Н.В. Моделирование депрессии на животных: поведение как основа методологии, критериев оценки и классификации. Журнал высшей нервной деятельности. 2015; 65 (6): 1-18
- Willner P. The validity of animal models of depression. Psychopharmacology. 1984; 83(1): 1-16.
- Dedic N., Walser S.M., Jan M. Deussing J.M. Mouse Models of Depression. In: Dr. Toru Uehara Chapter, ed. Psychiatric Disorders - Trends and Developments. InTech. 2011: 185-222.
- Калуев А.В. Экспериментальное моделирование тревожности и депрессии. Психофармакология. и биология. наркология. 2004; 4 (2-3): 663-70
- Willner, P., Mitchell, P. J. The validity of animal models of predisposition to depression. Behavioural Pharmacology. 2002; 13(3): 169-88
- Яузина Н.А., Комлева Ю.К., Салмина А.Б., Петрова М.М., Морозова Г.А., Малиновская Н.А., Герцог Г.Е. Современные экспериментальные модели депрессии. Биомедицина. 2013; 1: 61-77
- Demin Ma. L., Kolesnikov K.A., Kharsko T.O., Zhu S.L., Yuan X., Kalueff X. Animal inflammation-based models of depression and their application to drug discovery. Expert Opinion on Drug Discovery. 2017; 12(10): 995-1009.
- Caldarone B. J., Zachariou V., King S. L. Rodent models of treatment-resistant depression. European Journal of Pharmacology. 2015; 753: 51-65.
- Hennessy M.B., Deak T., SchimlWebb P.A. Early attachment-figure separation and increased risk for laterdepression: potential mediation by proinflammatoryprocesses. Neurosci. Biobehav. Rev. 2010; 34(6): 782-90.
- Pournajafi-Nazarloo H., Partoo L., Yee J., Stevenson J., Sanzenbacher L., Kenkel W., Mohsenpour S.R.,Hashimoto K., Carter C.S. Effects of social isolation on mRNA expression for corticotrophin-releasing hormone receptors in prairie voles. Psychoneuroendocrinology. 2011; 36(6): 780-9.
- Кудрявцева Н.Н., Августинович Д.Ф., Коваленко И.Л., Бондарь Н.П. Развитие ангедонии под влиянием негативного опыта социальных взаимодействий у самцов мышей. Российский физиологический журнал им И.М. Сеченова. 2006; 92(3): 351-61
- Lanfumey L., Mannoury La Cour C., Froger N., Hamon M. 5-HT-HPA interactions in two models of transgenic mice relevant to major depression. Neurochem Res. 2000; 25: 1199-206.
- Song Cai Leonard, Brian E. The olfactory bulbectomised rat as a model of depression. Neuroscience & Biobehavioral Reviews. 2005; 29 (4-5): 627-47.
- Wang Y., Cui X.L., Liu Y.F., Gao F., Wei D., Li X.W. et al. LPS inhibits the effects of fluoxetine on depression-like behavior and hippocampal neurogenesis in rats. Progress in neuro-psychopharmacology & biological psychiatry. 2011; 35 (8): 1831-5.
- Sammut S., Bethus I., Goodall G. et al. Antidepressant reversal of interferon-alpha-induced anhedonia. Physiol Behav. 2002; 75: 765-72.
- Gourley S.L., Kiraly D.D., Howell J.L., Olausson P., Taylor J.R. Acute Hippocampal Brain-Derived Neurotrophic Factor Restores Motivational and Forced Swim Performance After Corticosterone. Biological Psychiatry. 2008; 64(10): 884-90.
- O’Neil Michael F., Moore Nicholas A. Animal models of depression: are there any? Human Psychopharmacology: Clinical and Experimental. 2003; 18 (4): 239-54.
- Аляутдин Р.Н., Романов Б.К., Гусейнов М.Д. и др. Экспериментальная скрининговая оценка стресспротекторного действия фитопрепаратов. Российский медицинский журнал. 2008; 3: 29-33
- Durgam Robert C. Rodent models of depression: learned helplessness using a triadic design in rats. Current Protocols in Neuroscience. 2001; 8.10B.1-8.10B.12.
- Willner P. Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation. Psychopharmacology (Berl). 1997; 134(4): 319-29.
- Su K., Lai H.C., Peng C.Y., Su W.P., Chang J.P., Pariante C.M. Interferon-alpha-induced depression: Comparisons between early- and late-onset subgroups and with patients with major depressive disorder. Brain Behav Immun. 2019; May 4. pii: S0889-1591(19)30035-2. doi: 10.1016/j.bbi.2019.04.032. [Epub ahead of print].